BR9815296A - Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina - Google Patents

Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina

Info

Publication number
BR9815296A
BR9815296A BR9815296-3A BR9815296A BR9815296A BR 9815296 A BR9815296 A BR 9815296A BR 9815296 A BR9815296 A BR 9815296A BR 9815296 A BR9815296 A BR 9815296A
Authority
BR
Brazil
Prior art keywords
carboxylic acid
derivatives
endothelin antagonists
pyrrolidine carboxylic
antagonists
Prior art date
Application number
BR9815296-3A
Other languages
English (en)
Inventor
Martin Winn
Steven A Boyd
Charles W Hutchins
Hwan-Soo Jae
Andrew S Tasker
Thomas W Von Geldern
Jeffrey A Kester
Ryan K Sorensen
Bruce G Szczepankiewicz
Kenneth J Henry
Gang Liu
Steven J Wittenberger
Steven A King
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/905,913 external-priority patent/US6162927A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9815296A publication Critical patent/BR9815296A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

"DERIVADOS DE áCIDO CARBOXìLICO 3-PIRROLIDINA E OUSO DOS MESMOS COMO ANTAGONISTAS ENDOTELINA". édescrito um composto de fórmula (I) , ou um sal farmaceuticamenteaceitável do mesmo, assim como um processo e intermediáriospara a preparação do mesmo, e um método de antagonizarendotelina.
BR9815296-3A 1997-08-04 1998-07-27 Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina BR9815296A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/905,913 US6162927A (en) 1994-08-19 1997-08-04 Endothelin antagonists
US4895598A 1998-03-27 1998-03-27
PCT/US1998/015479 WO1999006397A2 (en) 1997-08-04 1998-07-27 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists

Publications (1)

Publication Number Publication Date
BR9815296A true BR9815296A (pt) 2001-11-20

Family

ID=26726720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815296-3A BR9815296A (pt) 1997-08-04 1998-07-27 Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina

Country Status (16)

Country Link
EP (1) EP1003740A2 (pt)
JP (1) JP2001512119A (pt)
CN (1) CN1301264A (pt)
AU (1) AU748469B2 (pt)
BG (1) BG104216A (pt)
BR (1) BR9815296A (pt)
CA (1) CA2297894A1 (pt)
HU (1) HUP0003484A3 (pt)
IL (1) IL134175A0 (pt)
NO (1) NO20000542L (pt)
NZ (1) NZ502395A (pt)
PL (1) PL342500A1 (pt)
SK (1) SK1452000A3 (pt)
TR (4) TR200101233T2 (pt)
TW (1) TW552260B (pt)
WO (1) WO1999006397A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337230A1 (en) * 1998-07-15 2000-01-27 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
CA2442591A1 (en) * 2001-04-11 2002-10-31 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2007034406A1 (en) * 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CA2850166C (en) 2011-09-27 2019-12-03 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX368703B (es) 2013-02-28 2019-10-11 Amgen Inc Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN104262329A (zh) * 2014-10-22 2015-01-07 南京友杰医药科技有限公司 反式阿曲生坦的制备
WO2024022262A1 (zh) * 2022-07-25 2024-02-01 深圳信立泰药业股份有限公司 一种内皮素a(eta)受体拮抗剂化合物的盐及其制备方法和医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
WO1996006095A1 (en) * 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists
HUP9902316A3 (en) * 1996-02-13 2001-12-28 Abbott Lab 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing them
US5618949A (en) * 1996-07-12 1997-04-08 Abbott Laboratories Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds

Also Published As

Publication number Publication date
SK1452000A3 (en) 2001-05-10
CA2297894A1 (en) 1999-02-11
WO1999006397A2 (en) 1999-02-11
HUP0003484A3 (en) 2002-02-28
TR200101234T2 (tr) 2002-06-21
BG104216A (bg) 2000-12-29
NO20000542D0 (no) 2000-02-02
NZ502395A (en) 2002-08-28
TR200101233T2 (tr) 2002-06-21
NO20000542L (no) 2000-04-04
WO1999006397A3 (en) 1999-12-09
AU8592198A (en) 1999-02-22
IL134175A0 (en) 2001-04-30
JP2001512119A (ja) 2001-08-21
EP1003740A2 (en) 2000-05-31
CN1301264A (zh) 2001-06-27
PL342500A1 (en) 2001-06-04
AU748469B2 (en) 2002-06-06
TR200000993T2 (tr) 2000-12-21
TR200501137T2 (tr) 2005-12-21
HUP0003484A2 (hu) 2002-01-28
TW552260B (en) 2003-09-11

Similar Documents

Publication Publication Date Title
BR9815296A (pt) Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina
ES2179881T3 (es) Antagonistas de endotelina.
PT894084E (pt) Derivados de acido cinamico e sua utilizacao como antagonistas de integrina
FI902661A0 (fi) Menetelmä angiotensiini-II-antagonisteina aktiivisten 3-(2'-(substituoitu)bifen-4-yyli)metyyli-3H-imidatso/4,5-b/pyridiiniyhdisteiden valmistamiseksi
IS2863B (is) Arípíprazóllausn til gjafar um munn
EP0664289A3 (en) Isoquinolines
IE894048L (en) New therapeutically active compound and a process for its¹preparation
AU2323897A (en) Cyclopropyl alkanoic acid derivatives
CA2168829A1 (en) Paroxetine hydrochloride anhydrate forms a,b,c and d
EP1334719A3 (en) Pentafluorobenzenesulfonamides and analogs
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
GB9322643D0 (en) Lactam derivatives
EP1609790A3 (en) Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
EP0302525A3 (en) Quinolones as antibacterial agents
DE69332259T2 (de) Kondensierte Thiadiazolderivate, Verfahren zu ihrer Herstellung und deren Verwendung
AU4629796A (en) 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
ES2138181T3 (es) Heterociclos biciclicos como antagonistas de la neurokinina.
TR199800531T1 (xx) NMDA antagonistleri olarak tetrahidrokinolinler.
WO1999026932A8 (en) By amidino group substituted heterocyclic derivatives and their use as anticoagulants
EP0806421A4 (en) DERIVATIVES OF CHINOLINE CARBONIC ACID
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AR010359A1 (es) Grupo heterociclico sustituido; antagonista de receptores de endotelina que lo comprende; derivado de acido carbonico heterociclico que lo incluye;combinaciones y preparaciones de medicamentos de este ultimo.
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
IT1260444B (it) Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
ES2182029T3 (es) Derivados de acido 4-(benzo-1,3-dioxolil) pirrolidin-3-carboxilico como antagonistas de endotelina.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements